Launching the patient site experience for a breakthrough microbiome therapy

In April 2023, Seres Therapeutics received FDA approval for VOWST—the first and only oral microbiome therapeutic for recurrent C. diff infections, the most common hospital-acquired infection in the U.S. To support the launch, we designed and developed a patient website that would educate prospective patients, build trust, and drive enrollment.

As the lead UX designer, I was responsible for building the site’s architecture, wireframes, and prototype, conducting usability testing, and guiding the implementation. Given the high-profile nature of the launch, we had to deliver quickly and accurately, navigating tight timelines and regulatory hurdles.

The result was a successful launch with the campaign and website winning numerous awards and generating 23,000 site visits, 52 engagement rate, and 7% conversion rate in the first month. The campaign ultimately contributed to over 2,800 patient enrollment forms and more than 2,000 patient starts by the end of 2023.